home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Improved Development and Regulation of Transdermal Systems

 
  April 14, 2011  
     
 
Sheraton National Hotel, Arlington, VA, USA
Sep 15 2011 7:00AM - Sep 16 2011 5:00PM


Improve All Aspects of the Design, Development, Manufacturing, and Regulation of Transdermal Drug Delivery Systems.

The first US transdermal drug delivery system (TDDS) was approved by the FDA more than 30 years ago. Despite this length of time and the advancement of science in many other pharmaceutical fields, little has changed or evolved in the development, control and regulation of these products. Over the years, various product quality problems have been reported by patients and practitioners. Some of these quality problems have safety and efficacy implications that have led to the recall of numerous batches of products and, in some cases, the temporary or permanent removal of the product from the market. This FDA-cosponsored workshop will offer a multidisciplinary and crossfunctional look at TDDSs to improve the development, design, manufacturing, quality, clinical performance, safety and regulation of these products.

 

Co-sponsored by FDA and DIA

 

 Event Code:

11021
 
 
Organized by: DIA
Invited Speakers: See website for speaker information
 
Deadline for Abstracts: Call contact
 
Registration: Melissa Matta, Program Developer
Phone +1.215.442.6158 
Fax +1.215.442.6199
E-mail: melissa.matta@diahome.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.